Machado-Joseph disease (MJD/SCA3) is the most common form of dominantly inherited ataxia 35 worldwide. The disorder is caused by an expanded CAG repeat in the ATXN3 gene. Past studies 36 have revealed that the length of the expansion partly explains the disease age at onset (AO) 37 variability of MJD, which is confirmed in this study. Using a total of 786 MJD patients from five 38 different geographical origins, a genome-wide association study (GWAS) was conducted to 39 identify additional AO modifying factors that could explain some of the residual AO variability. 40 We identified nine suggestively associated loci (P < 1 × 10 −5 ). These loci were enriched for genes 41 involved in vesicle transport, olfactory signaling, and synaptic pathways. Furthermore, 42 associations between AO and the TRIM29 and RAG genes suggests that DNA repair mechanisms 43 might be implicated in MJD pathogenesis. Our study demonstrates the existence of several 44 additional genetic factors, along with CAG expansion, that may lead to a better understanding of 45 the genotype-phenotype correlation in MJD. 46 Keywords 47 65 collaborative studies are required to identify genetic modifiers in MJD, as well as replicate the 66 findings of such studies [8]. 67 Previously, Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium carried out a GWA 68 approach of HD individuals to reveal genetic modifiers of AO in HD [9,10]. A total of eleven [9]
Machado-Joseph disease, ATXN3, MJD/SCA3, age at onset, modifier, GWAS 48 Introduction 49 Machado-Joseph disease, also known as spinocerebellar ataxia type 3 (MJD/SCA3), is an 50 autosomal dominant neurodegenerative disorder that is characterized by progressive cerebellar 51 ataxia and pyramidal signs, which can be associated with a complex clinical picture and includes 52 extrapyramidal signs or amyotrophy [1, 2] . MJD is caused by an abnormal CAG trinucleotide 53 repeat expansion in exon 10 of the ataxin-3 gene (ATXN3), located at 14q32.1. Deleterious 54 expansions consensually contain 61 to 87 CAG repeats, whereas wild type alleles range from 12 55 to 44 [2] . 56 As with other diseases caused by repeat expansions, such as Huntington's disease (HD) and other 57 spinocerebellar ataxias, there is an inverse correlation between expanded repeat size and the age 58 at which pathogenesis leads to disease onset [3] . Depending on the cohort structure, the size of the 59 repeat expansion explains 55 to 70% of the age at onset (AO) variability in MJD, suggesting the 60 existence of additional modifying factors [3, 4] . Although several genetic factors have been 61 proposed as modifiers, such as CAG repeat size of normal ATXN3 (SCA3), HTT (HD), ATXN2 62 (SCA2) and ATN1 (DRPLA) alleles, APOE status, and expression level of HSP40 [4,5,6], these 63 were not replicated by subsequent studies [7, 8] . Since CAG tract profile and allelic frequencies 64 of the potential modifier loci can have unique characteristics in different populations, large study, we performed the first GWAS to identify some possible genetic modifiers of AO in MJD. 71 First, we assessed the relationship between AO and size of the expanded (CAGexp) and normal 72 (CAGnor) alleles, biological sex and geographical origin. Next, we determined a residual AO for 73 each subject, which is the difference between the measured AO and the predicted/estimated AO 74 from expanded CAG repeat size alone. Using the residuals as a quantitative phenotype for a 75 GWAS, we looked for genetic factors that modulate AO in MJD.
76

Methods
77
Study subjects
78
A total of 786 MJD patients from five distinct geographical origins (Portugal, Brazil, North 79 America, Germany and Australia) were included in the present study. The overall average age at 80 onset (standard deviation) was 38 (± 1.82) years, with a 1:1 male to female ratio. All subjects 81 provided informed consent, and the study was approved by the respective institutional review 82 boards. Detailed cohort demographics are shown in Supplementary Table 1 . GeneMapper software [12] . A stepwise regression model was performed to assess the correlation 90 between AO and CAGexp size, as well as gender, origin, CAGnor size, and interaction between these 91 variables. Residual AO was calculated for each subject by subtracting individual's expected AO 92 based upon CAGexp size from actual AO, to be used as the primary phenotype for following genetic 93 approach.
94
Genotyping, quality control and imputation 95 Samples were genotyped using the Global Screening Array v.1.0 from Illumina (636,139 markers). sex, and the first three principal components based on the scree plot ( Supplementary Figure 1) .
113
The --mlma-loco option, which takes into account the difference in allele frequency between 114 populations, was used to control for population structure. QQ plots and Manhattan plots were 115 generated in FUMA v.1.3.4 [18]. Regional association plots were generated using LocusZoom
116
[19] ( Supplementary Figure 3) .
117
Functional annotation of SNPs
118
Genomic risk loci were defined using SNP2GENE function implemented in FUMA. Independent 119 suggestive SNPs (P < 1 × 10 −5 ) with a threshold of r 2 < 0.6 were selected within a 250 kb window.
120
The UK Biobank release 2 European population consisting of randomly selected 10,000 subjects 
Results
143
The inverse correlation between CAGexp and age at onset 144 In the first phase of the study, the expanded ATXN3-CAG repeat lengths of 786 MJD patients were Table 4 ). None of these HD-AO modifiers reached the genome-wide suggestive threshold. However, two variants rs144287831 (P = 0.02, effect size = -0.98) and 179 rs1799977 (P = 0.02, effect size = -0.98) in the MLH1 locus were found to be nominally associated 180 with a later AO in MJD.
181
Pathway and gene-set enrichment analysis 182
A gene-set enrichment and pathway analysis was conducted using i-GSEA4GWAS. Various 183 approaches and algorithms are currently in use to conduct similar analyses. To be able to make 184 better comparisons with other studies that may use different approaches, we performed a secondary 185 gene-set enrichment and pathway analysis using the VEGAS2 and PASCAL software 186 ( Supplementary Tables 5-7) . We also used these results for replication purposes in our own study.
187
A total of 13 overrepresented pathways were found, after FDR-multiple testing correction (q-value 188 < 0.05) in the primary GSEA analysis and replicated using at least one of the secondary gene-set 189 enrichment algorithms (Table 2) . Overall, the most significantly enriched gene-sets and pathways Using five cohorts from different geographical origins, we performed the first GWAS to examine 195 the presence of genetic factors that could modify AO in MJD. We identified a total of nine loci 196 that were potentially associated with either an earlier or later AO. Concomitantly, we confirmed 197 the previously observed negative correlation between CAGexp and AO [3] . It was shown previously 198 that normal ATXN3 allele (CAGnor) had a significant influence on AO of MJD [28]; however, several studies did not replicate this effect [6, 8] . Indeed, we did not observe an association between 200 CAGnor and AO. However, it had little contribution to our model, with a minor difference in the 201 correlation coefficient (ΔR 2 = 0.0012).
202
In our GWAS, the strongest signal is for the rs11529293 variant (P = 3.30 × 10 -6 ) within the in a previous study, we found variants in three transcription-coupled repair genes (ERCC6, RPA, 219 and CDK7) associated with different CAG instability patterns in MJD [35] . 220 We identified gene-sets enriched in olfactory signaling, vesicle transport, and synaptic pathways.
221
Olfactory dysfunction is one of the main non-motor symptoms that was already described in 222 patients with MJD [36, 37] . In a previous study, transplantation of olfactory ensheathing cells, 223 which are specialized glial cells of the primary olfactory system, were found to improve motor 224 function in an MJD mice model, and were suggested as a novel potential strategy for MJD Caenorhabditis elegans models of MJD. Therefore, the interaction between synaptic vesicles and 229 mutant aggregates supports the role of synaptic vesicle transport in the pathogenesis of MJD 230 [41, 42] . Overall, we suggest that these gene-sets and pathways might construct a larger molecular 231 network that could modulate the AO in MJD.
232
In summary, our study identified nine genetic loci that may modify the AO of MJD. Identification Table 2 . Pathways significant after multiple-correction (q < 5 x 10 -2 ) in the primary GSEA analysis and replicated using at least one of 261 the secondary gene-set enrichment algorithms. NA means that the pathway was not enriched by at least two significant genes in VEGAS. GO:0044456 synapse part < 1.0 x 10 -3 9.30 x 10 -3 1.25 x 10 -182 < 1.0 x 10 -6 < 1.0 x 10 -7 R-HSA:74217 purine salvage < 1.0 x 10 -3 1.06 x 10 -2 1.06 x 10 -2 2.15 x 10 -1 6.48 x 10 -3 GO:0045202 synapse < 1.0 x 10 -3 1.15 x 10 -2 1.15 x 10 -2 < 1.0 x 10 -6 < 1.0 x 10 -7 GO:0004177 aminopeptidase activity < 1.0 x 10 -3 1.50 x 10 -2 1.50 x 10 -2 3.41 x 10 -1 1.24 x 10 -2 GO:0008238 exopeptidase activity < 1.0 x 10 -3 1.80 x 10 -2 1.80 x 10 -2 2.80 x 10 -2 8.31 x 10 -3 GO:0006898 receptor mediated endocytosis < 1.0 x 10 -3 2.25 x 10 -2 2.25 x 10 -2 2.03 x 10 -1 6.64 x 10 -3 GO:0016917 GABA receptor activity < 1.0 x 10 -3 2.26 x 10 -2 2.26 x 10 -2 1.30 x 10 -4 2.30 x 10 -5 GO:0030140 trans Golgi network transport vesicle < 1.0 x 10 -3 2.36 x 10 -2 2.36 x 10 -2 2.80 x 10 -2 1.28 x 10 -1 GO:0009725 response to hormone stimulus < 1.0 x 10 -3 2.73 x 10 -2 2.73 x 10 -2 1.32 x 10 -1 1.30 x 10 -4 GO:0030425 Dendrite < 1.0 x 10 -3 3.86 x 10 -2 3.86 x 10 -2 < 1.0 x 10 -6 < 1.0 x 10 -7 
